NEOADJUVANT IMMUNOTHERAPY BY CONTINUOUS INTRA-ARTERIAL INFUSION OF RECOMBINANT INTER-LEUKIN-2 (rIL-2) IN PATIENTS (PTS) WITH LOW STAGE BLADDER CANCER.